ASCO 2025

De-escalating therapy - a step forward

TRADE: Abemaciclib in eBC

Risk according to NATALEE / MonarchE in WSG-ADAPT trial

WSG: HER2+ pooled analysis

Intraoperative dose escalation helps to reach targeted…

AI and ADCs: Precision diagnostics & safer rechallenge…

Triple therapy 1st line | double therapy 2nd line - new…

A new standard for endocrine-resistant HR+ MBC?

SG + Pembro in aTNBC: a new standard of care?

New compounds - new approaches: TNBC | HR+ | HER2+

SERENA-6 - a challenging strategy?

Next-gen endocrine therapies and ADCs: Updates from…

Re-exposition and ILD

Vepdegestrant for treatment of ER+/HER2- aBC

Future new SOC for PD-L1-positive mTNBC

Additional ADC effective for untreated TNBC

New firstline SOC for HER2+ metastatic BC

A new first-line therapy for TNBC

T-DXd: Detecting ILD and treat again

ASCENT-04

New AKT/PIK3 Antagonist for treatment of mBC after…

New treatment option in first line of metastatic TNBC

SG + Pembrolizumab might become SOC for PD-L1-positive…

Ipataserib + Fulvestrant improves PFS in PIK3CA-altered…

ABC for metastatic TNBC

Additional chemo-free option for TNBC

Effective ADC for HER2+ mBC with brain metastases

Liquid biopsy as a navigator for personalized therapy…

Sac-TMT for metastatic TNBC

New SOC in first-line treatment for primary endocrine…

Un nouveau traitement de première ligne pour le TNBC

Analisi finale della OS dello studio INAVO-120

SG + Pembrolizumab podría convertirse en el tratamiento…

Una nuova terapia di prima linea per il TNBC

Vepdegestrant per il trattamento di ER+/HER2- aBC

Ipatasertib + Fulvestrant mejora la supervivencia libre…

Nuova opzione di trattamento in prima linea per il TNBC…

PARP-inhibitor combinations in advanced prostate cancer

The role of ARPIs in mHSPCThe role of ARPIs in mHSPC

Personalized In Situ Immunotherapy SYNC-T Shows High…

CAN-2409 Offers First New Option in 20 Years

Combination of LU-PSMA and immunotherapy, EVOLUTION…

Adding EZH2 to Enzalutamide to decrease the development…

Localized CSPC - innovations

New way of treatment for PCa

Niraparib + Abiraterone Improves Outcomes in…

Stereotactic beam radiation therapy 2.0

Immuntherapy - an evolution?

News of ANZUP trial

mHSPC - prognostification - indications on integration?

Rebirth of Rucaparib

Real world data from ironman registry confirms…

MMAI Model identifies patients who benfit from ARPI in…

Real-world data från Ironman: PSA nivå en viktig…

Evolution: Kombination av LuPSMA och immunterapi.

Sasanlimab + BCG: Practice-Changing Potential for…

Complete but Not Finished: EV+P cCR Data Extend the SOC…

ctDNA Clearance Confirms Added Value of Perioperative…

Response matters in advanced urothelial cancer patients…

New nectin-4 ADCs are coming

CREST Study: Promising Results with PD-1 Inhibitor…

UTUC - enlighted

NIAGARA study and circulating tumor DNA

mUC EVP + subsequent therapies

Benefit of IO/IO therapy in mUC

New option for high-risk NMIBC

The role of sansalimab (+ SG) in BCG-naive and…

ASCO 2025 - Highlights for Bladder Cancer

Update on EV-PEM in the EV-302 study

Intensive caution of BCG Therapy

mUC - new approaches?

De nouveaux ADC pour la nectine-4 arrivent

El rol de sansalimab (+ SG) en el carcinoma urotelial…

La respuesta es importante en pacientes con cáncer…

HIF alfa sigue siendo una diana interesante en el RCC y…

¿Un nuevo factor pronóstico en el cáncer de vejiga? El…

PDIGREE: Real-Life Answers for Post-Ipi/Nivo Decisions

Casdatifan + Cabo – Too Early to Call It a Game…

9 Years of CheckMate 214 – Is Nivo + Ipi Still Holding…

Nivo + Ipi - Update & Insights

Allogeneic CD70 CAR T Cells in refractory RCC

Long-term outcome of Nnivo-Ipi in clear cell RCC

5-Year OS data from the KEYNOTE-564 study

HIF alpha still an interesting target in RCC and other…

Zanzalitinib + Nivolumab +/- Relatlimab in Front-line…

New synergies? Radiotherapy and IO in Limited-Stage…

CM-816: The OS results are positive and demonstrate…

Updates in perioperative strategies in NSCLC

Neadjuvant targeted therapy

MRD-analysis of the AEGEAN-trial

ctDNA stratification

CheckMate 816: Update on OS-benefit

Chemoimmunotherapy followed by chemoradiotherapy

cTDNA in periop chemo-IO strategies

CM-816 : Les résultats de l'OS sont positifs et…

Actualizaciones en estrategias perioperatorias en NSCLC

Targeting rare mutations in metastatic NSCLC - HER2 and…

What is the future in the field of EGFR resistance?

Have we MET our target?

RELA-104-biomarker-analysis

Sevarbertinib – an additional option for HER2 exon 20…

Immunotherapy – before or after 3 p.m.?

TROP2 targets – where is first-line development…

Benefit of IO is depending on the time of day of…

Does the timing of IO-infusion impact survival?

GDPase-Inhibition 1st line in KRAS G12C Mut.: Improved…

HERTHENA-Lung02 unfortunately negative study -…

ADC as 3L in EGFR

ADC in the 3L beats docetaxel

Updates on ADCs in EGFR resistance

HER3-DXd: dissapointing negative trial

Time of day of immunotherapy is important

KRAS G12C: Can immunotherapy improve patient outcome…

HERTHENA-Lung02 étude malheureusement négative -…

Is er nog een plaats voor HER3-DXd in gevorderd NSCLC?

Actualizaciones sobre los ADC en la resistencia al EGFR

Hebben we ons doel gehaald?

New therapies to improve patient survival

New maintenance therapy for SCLC

Tarlatamab - a new SOC in second line

DeLLphi-304: Dramatic change in 2L-treatment in SCLC

The first positive maintenance therapy in SCLC

DeLLphi-304 : Changement radical dans le traitement de…

Exercise - The new old wonderdrug